Inclusion Criteria:

- Show evidence of a signed (personally or by a legally acceptable representative) and
dated informed consent document indicating that the patient has been informed of all
pertinent aspects of the trial.

- Females ≥ 18 years of age.

- Diagnosed with Stage II-III breast cancer.

- Subject is scheduled to undergo 4 cycles of TC chemotherapy (Taxotere and
cyclophosphamide, 75 and 600 mg/m2, respectively).

- ECOG Performance status of ≤ 2.

- White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet
count ≥ 150 × 109/L.

- Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST,
alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of
normal (ULN). Serum creatinine should be less than 1.7x ULN.

- All subjects must agree to use at least one of the following types of contraception:
intrauterine device, implantable progesterone device, progesterone intramuscular
injection, or oral contraceptive, which has been started at least one month prior to
visit one and will continue for the duration of the trial. The contraceptive patch
or condom use with spermicide are also acceptable forms of contraception as long as
they will be used continually throughout the duration of the trial.

Exclusion Criteria:

- Subject is <18 or ≥ 75 years of age.

- Disease progression has occurred while receiving a taxane regimen.

- Subject has undergone radiation therapy within 4 weeks of enrollment.

- Subject has undergone bone marrow or stem-cell transplantation.

- Subject has a history of prior malignancy other than breast cancer.

- Subjects that have used G-CSF within 6 weeks of the screening period are also
excluded

- Subject has had chemotherapy within 365 days of screening

- Subject has documented congestive heart failure, cardiomyopathy or myocardial
infarction by clinical diagnosis, ECG test, or any other relevant test.

- History of alcohol or drug abuse that would interfere with the ability to be
compliant with the study procedure.

- Unwillingness to participate in the study.

- Any underlying medical condition that, in the Investigator's opinion, would make the
administration of study drug hazardous to the patient or that would obscure the
interpretation of adverse events.

- Receiving other investigational drugs or biologics within 1 month or five half lives
of enrollment.

- Any condition, which can cause splenomegaly.

- Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel
disease.

- ALT, AST, alkaline phosphatase > 2.5 upper limit of normal.

- Patients with active infection, or known to be infected with chronic active Hepatitis
B within the last 1 year (unless shown at the time of study entry to be Hepatitis B
antigen negative), or having any history of Hepatitis C.

- Women who are pregnant or breast-feeding.

- Patients known to be seropositive for HIV, or who have had an AIDS defining illness
or a known immunodeficiency disorder.

- Patients with a history of tuberculosis or exposure to tuberculosis. Patients that
have received a prior chest X-ray for suspicion of tuberculosis are also excluded
unless they have been confirmed to be PPD negative or they had latent tuberculosis
that has been previously treated.

- Subjects with Sickle Cell disease

- Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim'
filgrastim, or any other component of the study drug.